Ads
related to: short-term stock investment strategies
Search results
Lyft or Uber Stock: Which Is the Better Investment?
GoBankingRates via AOL· 6 days agoInvesting in ride-sharing companies may seem like a no-brainer. Ride-sharing stocks have climbed steadily over the past few years, with the two biggest...
Earnings call: Dollar Tree reviews Family Dollar amid growth strategy By Investing.com
Investing.com· 8 hours agoThe company announced in its first quarter earnings call that it saw a consolidated net sales...
UiPath stock downgraded by Needham amid CEO change and strategy shift By Investing.com
Investing.com· 7 days agoOn Thursday, Needham shifted its stance on UiPath Inc. (NYSE:PATH) stock, moving from a Buy to a...
Zacks Investment Ideas feature highlights: QQQ, SMH, Nvidia and Arm Holdings
Zacks· 2 days agoQQQ, SMH, Nvidia and Arm Holdings are part of the Zacks Investment Ideas article.
Upstart CFO Sanjay Datta sells $25,490 in company stock By Investing.com
Investing.com· 5 hours agoSanjay Datta, the Chief Financial Officer of Upstart (NASDAQ:UPST) Holdings, Inc. (NASDAQ:UPST), has...
Will Bitcoin ETFs Soar on Sooner-Than-Expected Fed Rate Cut?
Zacks via Yahoo Finance· 12 hours agoTraders are increasingly pricing in the likelihood of a Fed rate cut as early as September following...
How to trade mutual funds
Bankrate via Yahoo Finance· 1 day agoYou’ll want to think about the type of fund you’re looking for based on your investment goals. When you find a fund you’re interested in, be sure to read...
Recent Price Trend in Premier Foods (PRRFY) is Your Friend, Here's Why
Zacks via Yahoo Finance· 3 days agoPremier Foods (PRRFY) could be a solid choice for shorter-term investors looking to capitalize on...
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
Zacks via Yahoo Finance· 17 hours agoImage Source: Zacks Investment Research Booming Diabetes Market Bodes... Diabetes team is vigorously...
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Motley Fool via Yahoo Finance· 2 days agoAs Intellia's path to the market is much longer than CRISPR Therapeutics', there's a chance that it...
